Literature DB >> 29680966

Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat.

Anna Popelíková1, Štěpán Bahník2, Veronika Lobellová1, Jan Svoboda3, Aleš Stuchlík4.   

Abstract

RATIONALE: There is a persistent pressing need for valid animal models of cognitive and mnemonic disruptions (such as seen in Alzheimer's disease and other dementias) usable for preclinical research.
OBJECTIVES: We have set out to test the validity of administration of biperiden, an M1-acetylcholine receptor antagonist with central selectivity, as a potential tool for generating a fast screening model of cognitive impairment, in outbred Wistar rats.
METHODS: We used several variants of the Morris water maze task: (1) reversal learning, to assess cognitive flexibility, with probe trials testing memory retention; (2) delayed matching to position (DMP), to evaluate working memory; and (3) "counter-balanced acquisition," to test for possible anomalies in acquisition learning. We also included a visible platform paradigm to reveal possible sensorimotor and motivational deficits.
RESULTS: A significant effect of biperiden on memory acquisition and retention was found in the counter-balanced acquisition and probe trials of the counter-balanced acquisition and reversal tasks. Strikingly, a less pronounced deficit was observed in the DMP. No effects were revealed in the reversal learning task.
CONCLUSIONS: Based on our results, we do not recommend biperiden as a reliable tool for modeling cognitive impairment.

Entities:  

Keywords:  Anticholinergics; Learning; Memory; Morris water maze; Muscarinic receptors; Rat

Mesh:

Substances:

Year:  2018        PMID: 29680966     DOI: 10.1007/s00213-018-4899-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

Review 1.  The muscarinic system, cognition and schizophrenia.

Authors:  Sean P Carruthers; Caroline T Gurvich; Susan L Rossell
Journal:  Neurosci Biobehav Rev       Date:  2015-05-21       Impact factor: 8.989

Review 2.  Nicotinic receptors in addiction pathways.

Authors:  Frances M Leslie; Celina Y Mojica; Daisy D Reynaga
Journal:  Mol Pharmacol       Date:  2012-12-17       Impact factor: 4.436

Review 3.  Power failure: why small sample size undermines the reliability of neuroscience.

Authors:  Katherine S Button; John P A Ioannidis; Claire Mokrysz; Brian A Nosek; Jonathan Flint; Emma S J Robinson; Marcus R Munafò
Journal:  Nat Rev Neurosci       Date:  2013-04-10       Impact factor: 34.870

4.  Amnesic effects of the anticholinergic drugs, trihexyphenidyl and biperiden: differences in binding properties to the brain muscarinic receptor.

Authors:  Y Kimura; M Ohue; T Kitaura; K Kihira
Journal:  Brain Res       Date:  1999-07-10       Impact factor: 3.252

Review 5.  The cholinergic system and spatial learning.

Authors:  Serena Deiana; Bettina Platt; Gernot Riedel
Journal:  Behav Brain Res       Date:  2010-11-23       Impact factor: 3.332

6.  A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

7.  Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram.

Authors:  Anke Sambeth; Wim J Riedel; Inge Klinkenberg; Seppo Kähkönen; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2014-12-04       Impact factor: 4.530

Review 8.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

9.  Effects of biperiden and acute tryptophan depletion and their combination on verbal word memory and EEG.

Authors:  Laura G J M Borghans; Arjan Blokland; Anke Sambeth
Journal:  Psychopharmacology (Berl)       Date:  2017-02-16       Impact factor: 4.530

Review 10.  Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.

Authors:  Daniel J Foster; Derrick L Choi; P Jeffrey Conn; Jerri M Rook
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-28       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.